Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;51(6):1546-53.
doi: 10.1194/jlr.P002816. Epub 2009 Dec 2.

Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database

Philip J Barter  1 , Gunnar Brandrup-Wognsen, Mike K Palmer, Stephen J Nicholls
Affiliations

Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database

Philip J Barter et al. J Lipid Res. 2010 Jun.

Abstract

The relationship between statin-induced increases in HDL cholesterol (HDL-C) concentration and statin-induced decreases in LDL cholesterol (LDL-C) is unknown. The effects of different statins on HDL-C levels, relationships between changes in HDL-C and changes in LDL-C, and predictors of statin-induced increases in HDL-C have been investigated in an individual patient meta-analysis of 32,258 dyslipidemic patients included in 37 randomized studies using rosuvastatin, atorvastatin, and simvastatin. The HDL-C raising ability of rosuvastatin, and simvastatin was comparable, with both being superior to atorvastatin. Increases in HDL-C were positively related to statin dose with rosuvastatin and simvastatin but inversely related to dose with atorvastatin. There was no apparent relationship between reduction in LDL-C and increase in HDL-C, whether analyzed overall for all statins (correlation coefficient = 0.005) or for each statin individually. Percentage increase in apolipoprotein A-I was virtually identical to that of HDL-C at all doses of the three statins. Baseline concentrations of HDL-C and triglyceride (TG) and presence of diabetes were strong, independent predictors of statin-induced elevations of HDL-C. Statins vary in their HDL-C raising ability. The HDL-C increase achieved by all three statins was independent of LDL-C decrease. However, baseline HDL-C and TGs and the presence of diabetes were predictors of statin-induced increases in HDL-C.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Relationship between changes in concentrations of HDL-C and apoA-I during treatment with atorvastatin at 10, 20, 40, or 80 mg/day, rosuvastatin at 5, 10, 20, or 40 mg/day, or simvastatin at 10, 20, 40, or 80 mg/day. The diagonal lines depict a 1:1 relationship.
Fig. 2.
Fig. 2.
Relationship between changes in concentrations of HDL-C and LDL-C. Individual data for all patients (38,199 patient exposures) receiving any dose of rosuvastatin, atorvastatin, or simvastatin are shown (r = 0.02).
Fig. 3.
Fig. 3.
Impact of baseline concentrations of HDL-C, plasma TG, and LDL-C and patient characteristics on changes in HDL-C during treatment with rosuvastatin at either 10 mg or 40 mg. Results are means (95% CI). BMI, body mass index; Q, quintile (see text for definition).
Fig. 4.
Fig. 4.
Impact of baseline concentrations of HDL-C, plasma TG, and LDL-C and patient characteristics on changes in HDL-C during treatment with atorvastatin at either 20 mg or 80 mg. Results are means (95% CI). BMI, body mass index; Q, quintile (see text for definition).
See this image and copyright information in PMC

References

    1. Baigent C., Keech A., Kearney P. M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., et al. ; Cholesterol Treatment Trialists' (CTT) Collaborators. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 366: 1267–1278. - PubMed
    1. Sipahi I., Nicholls S. J., Tuzcu E. M., Nissen S. E. 2006. Coronary atherosclerosis can regress with very intensive statin therapy. Cleve. Clin. J. Med. 73: 937–944. - PubMed
    1. McTaggart F., Jones P. 2008. Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc. Drugs Ther. 22: 321–338. - PMC - PubMed
    1. Nicholls S. J., Tuzcu E. M., Sipahi I., Grasso A. W., Schoenhagen P., Hu T., Wolski K., Crowe T., Desai M. Y., Hazen S. L., et al. 2007. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 297: 499–508. - PubMed
    1. Jones P. H., Davidson M. H., Stein E. A., Bays H. E., McKenney J. M., Miller E., Cain V. A., Blasetto J. W. 2003. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 92: 152–160. - PubMed

Publication types